• Explore /
  • Poster
  • / Prognostic factors in stage 4 neuroblastoma treated with busulphan-melphalan: Report from the European HR-NBL1/Siopen trial.

Prognostic factors in stage 4 neuroblastoma treated with busulphan-melphalan: Report from the European HR-NBL1/Siopen trial.

Abstract Poster

Authors

Ruth Ladenstein

Ruth Ladenstein

St. Anna Children's Hospital and Research Institute for the SIOP Europe Neuroblastoma Group, Paediatric Haematology/Oncology, Vienna, Austria

Ruth Ladenstein , Ulrike Poetschger , Martin Elliott , Roberto Luksch , Victoria Castel , Isaac Yaniv , Vassilios Papadakis , Genevieve Laureys , Josef Malis , Walentyna Balwierz , Ellen Ruud , Per Kogner , Henrik Schroeder , Ana Forjaz De Lacerda , Maja Beck Popovic , Pavel Bician , Miklos Garami , Toby Trahair , Andrew DJ Pearson , Dominique Valteau Couanet

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Pediatric Oncology

Track

Pediatric Oncology

Sub Track

Pediatric Solid Tumors

Clinical Trial Registration Number

NCT01704716

Citation

J Clin Oncol 34, 2016 (suppl; abstr 10527)

DOI

10.1200/JCO.2016.34.15_suppl.10527

Abstract #

10527

Poster Bd #

218

Abstract Disclosures

Similar Posters

First Author: Keith Holmes

First Author: Elizabeth Sokol

First Author: Kevin M. Campbell

First Author: Ruth L Ladenstein